STOCK TITAN

Immix Biopharma Inc - IMMX STOCK NEWS

Welcome to our dedicated news page for Immix Biopharma (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immix Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immix Biopharma's position in the market.

Rhea-AI Summary
Immix Biopharma (IMMX) announces that updated NXC-201 clinical data has been accepted for oral presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy. The presentation will focus on next-generation CAR-T therapy for relapsed/refractory AL amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
-
Rhea-AI Summary
Immix Biopharma, Inc. selects Memorial Sloan Kettering Cancer Center as lead clinical site for NXC-201 clinical trial in AL Amyloidosis. NXC-201 CAR-T therapy offers hope for relapsed/refractory patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary
Immix Biopharma, Inc. launches new AL Amyloidosis awareness campaign 'Be Proactive in AL™' targeting relapsed or refractory patients in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
none
Rhea-AI Summary
Immix Biopharma (IMMX) announces significant progress in the past 12 months, achieving FDA clearance for NXC-201 CAR-T therapy in AL Amyloidosis and multiple myeloma, with high response rates. The company received Orphan Drug Designation in the US and EU, expanding into a $25 billion market segment. Immix Biopharma plans to continue quarterly updates, select new indications, and dose US patients with NXC-201, positioning itself as a leading autoimmune CAR-T company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Immix Biopharma, Inc. has closed an underwritten public offering of 5,535,055 shares of its common stock, generating approximately $15 million in gross proceeds. The net proceeds will be used for NXC-201 clinical trials, working capital, and general corporate purposes. The offering was made pursuant to an effective 'shelf' registration statement and was managed by Titan Partners Group, a division of American Capital Partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
-
Rhea-AI Summary
Immix Biopharma, Inc. (
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
Rhea-AI Summary
Immix Biopharma, Inc. has announced the pricing of an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share, with expected gross proceeds of approximately $15 million. The company intends to use the net proceeds for NXC-201 clinical trials, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
-
Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) announced an underwritten public offering of its common stock to fund NXC-201 clinical trials, working capital, and general corporate purposes. The offering is subject to market conditions, with the company intending to use the net proceeds for various purposes. Titan Partners Group, LLC is acting as the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.89%
Tags
-
Rhea-AI Summary
Immix Biopharma, Inc. announced FDA labeling change notifications for approved CAR-T products, focusing on the potential of their CAR-T candidates to address the unmet medical need in relapsed/refractory AL Amyloidosis. The company highlighted the favorable tolerability profile and lack of neurotoxicity in their ongoing Phase 1b/2 clinical trial, as well as the absence of observed secondary T-cell malignancies. The Chief Executive Officer and Chief Financial Officer expressed confidence in the potential of NXC-201 to treat AL Amyloidosis and other autoimmune indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
Rhea-AI Summary
Immix Biopharma, Inc. (IMMX) announces Dr. Sanchorawala joining Nexcella Scientific Advisory Board. Dr. Sanchorawala co-authored a study leading to daratumumab becoming a first-line standard of care for AL Amyloidosis. The company aims to advance NXC-201, a promising CAR-T therapy for relapsed/refractory AL Amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
management
Immix Biopharma Inc

Nasdaq:IMMX

IMMX Rankings

IMMX Stock Data

72.85M
14.09M
45.91%
8.47%
1.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Los Angeles